Anaerobic blood culture isolates in a Norwegian university hospital: Identification by MALDI-TOF MS vs 16S rRNA sequencing and antimicrobial susceptibility profiles

APMIS

Volumn 123, Issue 9, 2015, Pages 749-758

  Handal, Nina ^a   Bakken Jørgensen, Silje ^a   Smith Tunsjø, Hege ^a   Johnsen, Bjørn Odd ^a   Leegaard, Truls Michael ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anaerobic bacteria; Antimicrobial susceptibility; MALDI TOF

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RNA 16S; ANTIINFECTIVE AGENT;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES; BLOOD CULTURE; CLOSTRIDIUM; FUSOBACTERIUM; GRAM POSITIVE ANAEROBIC COCCI; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREVOTELLA; PRIORITY JOURNAL; RNA SEQUENCE; UNIVERSITY HOSPITAL; BACTERIAL INFECTIONS; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; SEQUENCE ANALYSIS;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, RNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84938957749     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12410     Document Type: Article

References (56)

1. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55.
2. Nagy E, Urban E, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9.
3. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010;50(Suppl 1):S26-33.
4. Jamal W, Shahin M, Rotimi VO. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007. Anaerobe 2010;16:1-5.
5. Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004;53:1039-44.
6. Hecht DW, Osmolski JR, O'Keefe JP. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis 1993;16(Suppl 4):S357-60.
7. Sherwood JE, Fraser S, Citron DM, Wexler H, Blakely G, Jobling K, et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011;17:152-5.
8. Katsandri A, Papaparaskevas J, Pantazatou A, Petrikkos GL, Thomopoulos G, Houhoula DP, et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J Clin Microbiol 2006;44:3465-7.
9. Wareham DW, Wilks M, Ahmed D, Brazier JS, Millar M. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis 2005;40:e67-8.
10. Kalapila A, Pergam S, Pottinger P, Butler-Wu EW, Duchin J. Multidrug-Resistant Bacteroides fragilis - Seattle, Washington, 2013. Morbidity and Mortality Weekly Report. 2013, 30th August 2013.
11. Walsh TR, Onken A, Haldorsen B, Toleman MA, Sundsfjord A. Characterization of a carbapenemase-producing clinical isolate of Bacteroides fragilis in Scandinavia: genetic analysis of a unique insertion sequence. Scand J Infect Dis 2005;37:676-9.
12. Hartmeyer GN, Soki J, Nagy E, Justesen US. Multidrug-resistant Bacteroides fragilis group on the rise in Europe? J Med Microbiol 2012;61(Pt 12):1784-8.
13. Citron DM, Ostovari MI, Karlsson A, Goldstein EJ. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 1991;29:2197-203.
14. Bremmelgaard A, Jansen JE, Justesen T, Gottschau A. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group. APMIS 1994;102:446-50.
15. Appelbaum PC, Spangler SK, Cohen M, Jacobs MR. Comparison of the E-test and conventional agar dilution methods for susceptibility testing of gram-negative anaerobic rods. Diagn Microbiol Infect Dis 1994;18:25-30.
16. Bruker, editor. MALDI Biotyper 3.1 User Manual. 1st ed. Bremen, Germany: Bruker Daltonics, 2012.
17. Clinical and Laboratory Standards Institute. Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing. Approved Standard MM18-A. 1st ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
18. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved Standard M11-A8. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
19. EUCAST clinical breakpoints table, version 4.0 [Internet]. European Committee on Antimicrobial Susceptibility Testing. [cited 1st March 2014]. Available from: http://www.eucast.org/clinical_breakpoints/.
20. Pedersen RM, Marmolin ES, Justesen US. Species differentiation of Bacteroides dorei from Bacteroides vulgatus and Bacteroides ovatus from Bacteroides xylanisolvens - back to basics. Anaerobe 2013;24:1-3.
21. Culebras E, Rodriguez-Avial I, Betriu C, Gomez M, Picazo JJ. Rapid identification of clinical isolates of Bacteroides species by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. Anaerobe 2012;18:163-5.
22. Schmitt BH, Cunningham SA, Dailey AL, Gustafson DR, Patel R. Identification of anaerobic bacteria by Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry with on-plate formic acid preparation. J Clin Microbiol 2013;51:782-6.
23. Fedorko DP, Drake SK, Stock F, Murray PR. Identification of clinical isolates of anaerobic bacteria using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Eur J Clin Microbiol Infect Dis 2012;31:2257-62.
24. Coltella L, Mancinelli L, Onori M, Lucignano B, Menichella D, Sorge R, et al. Advancement in the routine identification of anaerobic bacteria by MALDI-TOF mass spectrometry. Eur J Clin Microbiol Infect Dis 2013;32:1183-92.
25. Brown K, Church D, Lynch T, Gregson D. Bloodstream infections due to Peptoniphilus spp.: report of 15 cases. Clin Microbiol Infect 2014;20:O857-60.
26. Wildeboer-Veloo AC, Harmsen HJ, Welling GW, Degener JE. Development of 16S rRNA-based probes for the identification of Gram-positive anaerobic cocci isolated from human clinical specimens. Clin Microbiol Infect 2007;13:985-92.
27. Veloo AC, Welling GW, Degener JE. Mistaken identity of Peptoniphilus asaccharolyticus. J Clin Microbiol 2011;49:1189.
28. Murphy EC, Frick IM. Gram-positive anaerobic cocci-commensals and opportunistic pathogens. FEMS Microbiol Rev 2013;37:520-53.
29. Veloo ACM, Knoester M, Degener JE, Kuijper EJ. Comparison of two matrix-assisted laser desorption ionisation-time of flight mass spectrometry methods for the identification of clinically relevant anaerobic bacteria. CMI 2011;17:1501-6.
30. Justesen US, Holm A, Knudsen E, Andersen LB, Jensen TG, Kemp M, et al. Species identification of clinical isolates of anaerobic bacteria: a comparison of two matrix-assisted laser desorption ionization-time of flight mass spectrometry systems. J Clin Microbiol 2011;49:4314-8.
31. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013;26:526-46.
32. Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ, Patel SN. Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. Anaerobe 2014;28:120-125.
33. Papaparaskevas J, Pantazatou A, Katsandri A, Houhoula DP, Legakis NJ, Tsakris A, et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008;62:137-41.
34. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012;56:1247-52.
35. Kommedal O, Nystad TW, Bolstad B, Digranes A. Antibiotic susceptibility of blood culture isolates of anaerobic bacteria at a Norwegian university hospital. APMIS 2007;115:956-61.
36. Hannula R, Iversen G. Resistance of Bacteroides species in Trondheim, Norway. Poster ECCMID 2008. Trondheim, Norway2008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/?term=hannula+2008.
37. Justesen US, Hansen F, Ostergaard C, Schonheyder HC, Hansen DS, Lemming LE, et al. High rates of reduced susceptibility in the Bacteroides fragilis group isolated from blood cultures-the first national survey in Denmark. Int J Antimicrob Agents 2013;42:188-90.
38. Shah HN, Olsen I, Bernard K, Finegold SM, Gharbia S, Gupta RS. Approaches to the study of the systematics of anaerobic, gram-negative, non-sporeforming rods: current status and perspectives. Anaerobe 2009;15:179-94.
39. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007;20:593-621.
40. Nguyen MH, Yu VL, Morris AJ, McDermott L, Wagener MW, Harrell L, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000;30:870-6.
41. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007;44:895-900.
42. Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 1998;26:1413-7.
43. Hecht DW. Routine anaerobic blood cultures: back where we started? Clin Infect Dis 2007;44:901-3.
44. Hung MN, Chen SY, Wang JL, Chang SC, Hsueh PR, Liao CH, et al. Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center. J Microbiol Immunol Infect 2005;38:436-43.
45. Phillips I, King A, Nord CE, Hoffstedt B. Antibiotic sensitivity of the Bacteroides fragilis group in Europe. European Study Group. Eur J Clin Microbiol Infect Dis 1992;11:292-304.
46. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011;17:147-51.
47. Seifert H, Dalhoff A, Group PS. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010;65:2405-10.
48. Wybo I, Van den Bossche D, Soetens O, Vekens E, Vandoorslaer K, Claeys G, et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2014;69:155-61.
49. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8.
50. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50(Suppl 1):S16-23.
51. Betriu C, Culebras E, Gomez M, Lopez F, Rodriguez-Avial I, Picazo JJ. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Antimicrob Agents Chemother 2008;52:2686-90.
52. Trevino M, Areses P, Penalver MD, Cortizo S, Pardo F, del Molino ML, et al. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe 2012;18:37-43.
53. Katsandri A, Avlamis A, Pantazatou A, Houhoula DP, Papaparaskevas J. Dissemination of nim-class genes, encoding nitroimidazole resistance, among different species of Gram-negative anaerobic bacteria isolated in Athens, Greece. J Antimicrob Chemother 2006;58:705-6.
54. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001.
55. Sandoe JA, Struthers JK, Brazier JS. Subdural empyema caused by Prevotella loescheii with reduced susceptibility to metronidazole. J Antimicrob Chemother 2001;47:366-7.
56. Mory F, Carlier JP, Alauzet C, Thouvenin M, Schuhmacher H, Lozniewski A. Bacteremia caused by a metronidazole-resistant Prevotella sp. strain. J Clin Microbiol 2005;43:5380-3.